Article
Genetic modification of Bacillus subtilis for production of D-chiro-inositol, an investigational drug candidate for treatment of type 2 diabetes and polycystic ovary syndrome.
Applied and environmental microbiology - 1 Feb 2006
Yoshida Ken-ichi, Yamaguchi Masanori, Morinaga Tetsuro, Ikeuchi Maya, Kinehara Masaki, Ashida Hitoshi
Abstract excerpt
D-chiro-inositol (DCI) is a drug candidate for the treatment of type 2 diabetes and polycystic ovary syndrome, since it improves the efficiency with which the body uses insulin and also promotes ovulation. Here, we report genetic modification of Bacillus subtilis for production of DCI from myo-inositol (MI). The B. subtilis iolABCDEFGHIJ operon encodes enzymes for the multiple steps of the MI catabolic pathway....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.